Neudata research | Kyber Data Science

Kyber Data Science

Visit website

Request a demo Claim this profile

Kyber Data Science is attending the

[]

About Kyber Data Science

DDQ available

Kyber Data Science, a division of TD Cowen, is one of the most robust and sophisticated sources for advantaged insight into real-time, real-world utilization of healthcare products, enabling investors to track underlying demand for nearly all relevant pharmaceutical and biopharma products across more than 100 tickers.

Kyber has unique visibility into many pharmacy and medical channel products that are often blocked through traditional data sources. Kyber provides granular KPIs as well as back-testing for the lowest prediction error and tracking beats & misses.

Kyber Data Science products

On chain data

New today

Request information

[{"title":"Healthcare claims and EMR data","url":"https://neudata.co/datasets/healthcare-claims-and-emr-data","publication_flag":null},{"title":"Consumer survey data","url":"https://neudata.co/additional-datasets/consumer-survey-data","publication_flag":null},{"title":"Cannabis POS data","url":"https://neudata.co/additional-datasets/cannabis-pos-data","publication_flag":null}]

Similar vendors to Kyber Data Science

Neudata has identified 20 vendors that have similar offerings to Kyber Data Science. Request the full report to find out more.

Advanced Technologies

Quality Assurance

Essential Supplies

NextGen Services

Innovative Strategies

Synergy Partners

Pioneer Solutions

Urban Developments

Noble Ventures

Visionary Concepts

Elite Marketing

Prime Consulting

Future Tech

Bright Ideas

Dynamic Systems

Global Services

Creative Designs

Smart Logistics

Green Innovations

Tech Solutions

News and intelligence related to Kyber Data Science

[{"title":"The US healthcare claims race","image":"https://neudata.co/rails/active_storage/representations/proxy/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZ0JkIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--11c1deb339c892b13265b068e2c3b2c908936b87/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCem9MWm05eWJXRjBTU0lJY0c1bkJqb0dSVlE2QzNKbGMybDZaVWtpRERZd01IZzBNREFHT3daVSIsImV4cCI6bnVsbCwicHVyIjoidmFyaWF0aW9uIn19--7ae9fca008c09185b871bf2fe86c179a519caa00/anshu-a-trz15aaL9cE-unsplash.jpg","url":"https://neudata.co/intelligence/the-us-healthcare-claims-race","publication_date":"2025-06-11","category":"Intelligence"},{"title":"Healthcare claims disruptions: What next?","image":"https://neudata.co/rails/active_storage/representations/proxy/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZ0ZSIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--840394b34a095a942ee137215240a49643591845/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCem9MWm05eWJXRjBTU0lJY0c1bkJqb0dSVlE2QzNKbGMybDZaVWtpRERZd01IZzBNREFHT3daVSIsImV4cCI6bnVsbCwicHVyIjoidmFyaWF0aW9uIn19--7ae9fca008c09185b871bf2fe86c179a519caa00/towfiqu-barbhuiya-w8p9cQDLX7I-unsplash.jpg","url":"https://neudata.co/intelligence/healthcare-claims-disruptions-what-next","publication_date":"2024-06-18","category":"Intelligence"},{"title":"Healthcare revisited – A quick 2023 bird’s-eye view","image":"https://neudata.co/rails/active_storage/representations/proxy/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBc3BLIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--2546ed8339bb6683b746f3e0adc4cec181a8ea4e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCem9MWm05eWJXRjBTU0lJY0c1bkJqb0dSVlE2QzNKbGMybDZaVWtpRERZd01IZ3pNVEVHT3daVSIsImV4cCI6bnVsbCwicHVyIjoidmFyaWF0aW9uIn19--b55e821fff1fb6a5277a641f9807539f25cc39cc/christina-victoria-craft-ZHys6xN7sUE-unsplash.jpg","url":"https://neudata.co/intelligence/healthcare-revisited-a-quick-2023-birds-eye-view","publication_date":"2023-09-27","category":"Intelligence"},{"title":"Alternative Data for Healthcare Investors (Part IV): Claims vs EHRs","image":"https://neudata.co/rails/active_storage/representations/proxy/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBc2RLIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--1a900f49c1104888b3f6d591f057f0b4893191cf/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCem9MWm05eWJXRjBTU0lJY0c1bkJqb0dSVlE2QzNKbGMybDZaVWtpRERZd01IZzBNREFHT3daVSIsImV4cCI6bnVsbCwicHVyIjoidmFyaWF0aW9uIn19--7ae9fca008c09185b871bf2fe86c179a519caa00/part-iv-HEADER.jpg","url":"https://neudata.co/intelligence/alternative-data-for-healthcare-investors-part-iv-claims-vs-ehrs","publication_date":"2019-09-12","category":"Intelligence"}]

Kyber Data Science risk check

Dataset type(s) - select all that apply.

Please highlight any of the following components that may be included in your categories selected above (Personal data, location data, demographic data, or other sensitive data elements).

Please list the data products this assessment covers.

Mauris eu cursus odio, sit amet aliquam sem.

How long have you been selling data?

Donec tempor, libero non ultrices volutpat.

Please highlight any relevant litigation or negative press.

Phasellus dolor tellus.

How many financial services firms are using your data (excluding corporate users and unpaid trialists)?

Cras mattis, turpis sit amet volutpat viverra.

Request access

[]

About Neudata

Neudata provides unbiased research and expert consultancy on data sources and use cases. We connect data buyers and sellers through our platform, creating efficiencies for people who work with data.

Our platform includes in-depth research on thousands of data vendors, which are evaluated on over 100 unique factors to ensure their usability for data buyers.

Data buyers: Discover, manage, stay ahead

We exist to simplify the complex world of data discovery. By guiding investment teams through sourcing, trialling and managing data, we empower them to focus on what they do best – generating alpha.

Let's get started

Are you Kyber Data Science?

Take control of your Neudata profile to ensure accurate representation of your data offerings and maximise visibility with qualified buyers in the investment space.

Claim your profile

Request a full version of this report

Neudata publishes in-depth research on data vendor products and offerings, including information on pricing and the competitive landscape. Fill out your details below to request a full version of this research report.

Founded

Kyber was launched in June 2018

Company history

Cowen launched its Kyber Data Science unit in June 2018. At the time, this was the first investment bank unit to proactively market alternative data as a standalone subscription service. Today, Kyber has built a portfolio of tailored data offerings including targeted market spotlights to track interconnected competitive dynamics, custom workbooks with essential launch KPIs, and patient assistance program utilization visibility to improve revenue predictions. Kyber has also built the best healthcare data scientist team in the financial services industry to support investors' success.

Office locations

NYC

Number of employees

11-50

Sources of funding

Kyber closed a $10m Series A financing round in August 2020, led by Cowen and Ian McKinnon, a former managing partner of Ziff Brothers Investments.

Contact name

John Smith

Contact role

Analyst